Dapagliflozin treatment in IgA nephropathy patients

Prospective obsevational study in IgA nephropathy patients treated with dapahliflozin

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220369

Enrollment

150

Registered

2022-10-07

Start date

2021-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Diagnosis of IgA nephropathy by renal biopsy (2) IgA nephropathy patients treated with dapagliflozin (3) 20 years of age and older at the time of consent acquisition (4) Receiving maximum tolerated dose of RAS inhibitors (excluding not tolerable case due to AE) (5) After completion of predonine treatment (6) eGFR more than 25 mL/min/1.73 m2 (7) Postive proteinuria (8) Patients who have been fully informed about their participation in this study, and who have given their free and voluntary written consent based on a thorough understanding of the subject's own

Exclusion criteria

Exclusion criteria: (1) Patients who are taking or may start steroids or other immunosuppressive drugs during the study period (2) Patients who cannot walk on their own and need assistance or a wheelchair to get to the hospital (3) Patients under treatment for malignant tumors (4) BMI less than 18 (5) Other exclusion criteria include patients deemed inappropriate as research subjects by the principal investigator A research subject is eligible if he/she meets all of the selection criteria and none of the exclusion criteria listed above

Design outcomes

Primary

Measure	Time frame
Change in proteinuria and eGFR from baseline	—

Contacts

Public ContactGohda Tomohito

Juntendo University Hospital

goda@juntendo.ac.jp+81-3-3813-3111

Outcome results